Grifols, S.A. (GIFLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Grifols, S.A. (GIFLF) with AI Score 52/100 (Hold). Grifols, S. A. is a global healthcare company specializing in plasma-derived therapies and diagnostic solutions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Grifols, S.A. (GIFLF) Healthcare & Pipeline Overview
Grifols, S.A., founded in 1940 and headquartered in Barcelona, is a global healthcare leader focused on plasma-derived therapies and diagnostic solutions. Operating across Bioscience, Hospital, Diagnostic, and Bio Supplies divisions, Grifols serves diverse healthcare needs, addressing chronic, rare, and life-threatening diseases with a comprehensive portfolio of products and services.
Investment Thesis
Grifols, S.A. presents a notable research candidate within the healthcare sector, driven by its leading position in plasma-derived therapies and diagnostic solutions. The company's consistent profitability, demonstrated by a 5.3% profit margin and 38.4% gross margin, underscores its operational efficiency. A key value driver is the increasing demand for plasma-derived products, fueled by an aging global population and advancements in medical treatments. Upcoming catalysts include the potential expansion of its product portfolio and geographic reach. However, investors should be aware of potential risks, including regulatory changes and competition from other players in the industry. Grifols' beta of 1.19 suggests a slightly higher volatility compared to the market, while its dividend yield of 1.60% provides a steady income stream for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $8.78 billion reflects Grifols' significant presence in the healthcare industry.
- P/E ratio of 16.01 indicates a reasonable valuation compared to its earnings.
- Profit margin of 5.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 38.4% highlights the efficiency of Grifols' production and sales processes.
- Dividend yield of 1.60% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Leading position in plasma-derived therapies.
- Diversified product portfolio.
- Global presence and distribution network.
- Strong R&D capabilities.
Weaknesses
- Dependence on plasma supply.
- Exposure to regulatory changes.
- High R&D costs.
- Competition from other players in the industry.
Catalysts
- Ongoing: Increasing demand for plasma-derived therapies due to the aging global population.
- Ongoing: Expansion of the company's product portfolio through R&D efforts.
- Upcoming: Potential strategic acquisitions to expand market share.
- Upcoming: Positive clinical trial results for new therapies in development.
- Ongoing: Geographic expansion into emerging markets with high growth potential.
Risks
- Potential: Fluctuations in plasma prices could impact profitability.
- Ongoing: Intense competition from other players in the plasma-derived therapies market.
- Potential: Regulatory changes could impact the company's operations and financial performance.
- Potential: Product liability claims could result in significant financial losses.
- Ongoing: Economic downturns could reduce demand for the company's products and services.
Growth Opportunities
- Expansion of Bioscience Division: Grifols can expand its Bioscience division by developing new plasma-derived therapies and increasing its market share in existing products. The global market for immunoglobulins, for example, is projected to reach $18.5 billion by 2028, presenting a significant growth opportunity for Grifols. This expansion can be achieved through increased R&D investment and strategic acquisitions.
- Geographic Expansion: Grifols has the opportunity to expand its geographic presence, particularly in emerging markets. These markets offer significant growth potential due to increasing healthcare spending and a growing demand for plasma-derived therapies. The company can leverage its existing infrastructure and partnerships to penetrate these markets effectively.
- Diagnostic Division Growth: The Diagnostic division can drive growth by developing and commercializing innovative diagnostic products that address unmet medical needs. The global market for diagnostic products is expected to grow at a CAGR of 5% over the next five years, driven by advancements in technology and increasing demand for personalized medicine. Grifols can capitalize on this trend by investing in R&D and strategic partnerships.
- Hospital Division Expansion: Grifols can expand its Hospital division by offering a wider range of non-biological pharmaceutical products, medical supplies, and medical devices. The global market for hospital supplies is projected to reach $45 billion by 2027, presenting a significant growth opportunity for Grifols. This expansion can be achieved through strategic acquisitions and partnerships.
- Bio Supplies Division Growth: The Bio Supplies division can drive growth by providing biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. The increasing demand for these materials, driven by advancements in biotechnology and personalized medicine, presents a significant growth opportunity for Grifols. The company can leverage its expertise and infrastructure to capitalize on this trend.
Opportunities
- Expansion into emerging markets.
- Development of new plasma-derived therapies.
- Growth in the diagnostic products market.
- Strategic acquisitions and partnerships.
Threats
- Fluctuations in plasma prices.
- Increased competition.
- Product liability claims.
- Economic downturns.
Competitive Advantages
- Specialized expertise in plasma-derived therapies.
- Extensive network of plasma donation centers.
- Strong relationships with healthcare providers and institutions.
- Proprietary manufacturing processes and technologies.
About GIFLF
Founded in 1940 in Barcelona, Spain, Grifols, S.A. has evolved into a global healthcare company specializing in plasma-derived therapies and diagnostic solutions. The company operates through four primary divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies. The Bioscience division is the core of Grifols' business, focusing on the research, development, production, and marketing of plasma-derived medicines. These therapies include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins, which are used to treat patients with chronic, rare, prevalent, and life-threatening diseases. The Hospital division provides non-biological pharmaceutical products, medical supplies, clinical nutrition products, intravenous therapy solutions, and medical devices. The Diagnostic division develops and commercializes diagnostic products used across the healthcare continuum, from prevention and screening to diagnosis, prognosis, and treatment monitoring. The Bio Supplies division offers biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. Grifols serves a wide range of customers, including public and private healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. The company has a technology collaboration agreement with Mondragon, further enhancing its innovation capabilities. With a global presence and a commitment to innovation, Grifols is dedicated to improving patient outcomes and advancing healthcare worldwide.
What They Do
- Procures plasma from donors.
- Manufactures therapeutic products from plasma.
- Develops and commercializes diagnostic products.
- Offers non-biological pharmaceutical products and medical supplies.
- Provides biological materials for life-science research.
- Markets plasma-derived medicines to treat chronic, rare, and life-threatening diseases.
Business Model
- Generates revenue from the sale of plasma-derived therapies.
- Earns revenue from the sale of diagnostic products and services.
- Profits from the sale of hospital supplies and medical devices.
- Derives income from providing biological materials for research and manufacturing.
Industry Context
Grifols operates in the drug manufacturing industry, which is characterized by intense competition, stringent regulatory requirements, and high research and development costs. The global market for plasma-derived therapies is experiencing steady growth, driven by the increasing prevalence of chronic diseases and advancements in medical technology. Grifols competes with other major players in the industry, including BDUUF (B. Braun Melsungen AG), CSPCY (CSL Limited), ESAIY (Eisai Co., Ltd.), ESALF (EssilorLuxottica SA), and KYKOF (Kyowa Kirin Co., Ltd.). The company's focus on innovation and strategic partnerships positions it favorably within this competitive landscape.
Key Customers
- Public and private healthcare providers
- Wholesalers and distributors
- Blood banks and hospitals
- National health systems
Financials
Chart & Info
Grifols, S.A. (GIFLF) stock price: Price data unavailable
Latest News
No recent news available for GIFLF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GIFLF.
Price Targets
Wall Street price target analysis for GIFLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GIFLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jose Ignacio Abia Buenache
CEO
Jose Ignacio Abia Buenache serves as the CEO of Grifols, S.A., leading a global workforce of 23,833 employees. His career history reflects a deep understanding of the healthcare industry, with extensive experience in strategic management and operational leadership. He is responsible for guiding Grifols' overall strategy, driving innovation, and ensuring the company's continued growth and success in the global market. His leadership is crucial in navigating the complexities of the plasma-derived therapies and diagnostic solutions sectors.
Track Record: Under Jose Ignacio Abia Buenache's leadership, Grifols has continued to expand its global presence and strengthen its position as a leader in plasma-derived therapies. Key achievements include strategic acquisitions, the development of innovative products, and the expansion of the company's R&D capabilities. His focus on operational efficiency and strategic partnerships has contributed to Grifols' consistent profitability and growth.
GIFLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing requirements or regulatory oversight, which increases the risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in GIFLF.
- Lower trading volume and wider bid-ask spreads can lead to price volatility.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- The OTC market is generally more susceptible to market manipulation.
- Delays in trade execution due to lower liquidity.
- Verify the company's registration and regulatory filings.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Grifols, S.A. is a well-established company with a long operating history.
- The company has a global presence and serves a wide range of customers.
- Grifols is a leader in the plasma-derived therapies market.
- The company has a technology collaboration agreement with Mondragon.
- The company employs over 23,000 employees.
Common Questions About GIFLF
What does Grifols, S.A. do?
Grifols, S.A. is a global healthcare company that specializes in plasma-derived therapies and diagnostic solutions. The company operates through Bioscience, Hospital, Diagnostic, and Bio Supplies divisions. Its core business involves the research, development, production, and marketing of plasma-derived medicines, including immunoglobulins, alpha-1 antitrypsin, and albumin. These therapies are used to treat patients with chronic, rare, and life-threatening diseases. Additionally, Grifols offers diagnostic products, hospital supplies, and biological materials for research and manufacturing, serving healthcare providers and institutions worldwide.
What do analysts say about GIFLF stock?
Analyst coverage of GIFLF is pending. Investors should conduct their own due diligence and consider various factors, including the company's financial performance, growth prospects, and industry trends. Key valuation metrics to consider include the P/E ratio, profit margin, and dividend yield. Growth considerations include the increasing demand for plasma-derived therapies and the company's expansion into new markets. The company's OTC listing may limit the availability of analyst coverage.
What are the main risks for GIFLF?
Grifols, S.A. faces several risks, including fluctuations in plasma prices, which can impact its profitability. Intense competition from other players in the plasma-derived therapies market poses a threat to its market share. Regulatory changes in the healthcare industry could affect its operations and financial performance. Product liability claims, inherent in the pharmaceutical industry, could result in significant financial losses. Additionally, economic downturns could reduce demand for its products and services. Investors should carefully consider these risks before investing in GIFLF.
What is Grifols, S.A.'s drug pipeline status?
The specific details of Grifols, S.A.'s drug pipeline are not available in the provided data. However, the company's Bioscience division focuses on the research, development, and production of plasma-derived medicines. These therapies include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins, which are used to treat patients with chronic, rare, prevalent, and life-threatening diseases. Investors should consult Grifols' official website or investor relations materials for the most up-to-date information on its clinical pipeline stages, key therapeutic areas, and upcoming catalysts.
What are the key growth opportunities for GIFLF in healthcare?
Grifols, S.A. has several key growth opportunities within the healthcare sector. These include expanding its Bioscience division by developing new plasma-derived therapies and increasing its market share in existing products. Geographic expansion, particularly in emerging markets with increasing healthcare spending, presents another significant opportunity. The Diagnostic division can drive growth by developing and commercializing innovative diagnostic products. Additionally, the Hospital and Bio Supplies divisions can expand by offering a wider range of products and services. These growth opportunities are driven by increasing healthcare spending, advancements in medical technology, and a growing demand for personalized medicine.
What are the key factors to evaluate for GIFLF?
Grifols, S.A. (GIFLF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Leading position in plasma-derived therapies.. Primary risk to monitor: Potential: Fluctuations in plasma prices could impact profitability.. This is not financial advice.
How frequently does GIFLF data refresh on this page?
GIFLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GIFLF's recent stock price performance?
Recent price movement in Grifols, S.A. (GIFLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leading position in plasma-derived therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.